The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
C. P. Schroder
No relevant relationships to disclose
J. V. Pedersen
No relevant relationships to disclose
S. Chua
No relevant relationships to disclose
C. Swanton
Consultant or Advisory Role - Novartis
Research Funding - Novartis
M. Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Roche
S. Ide
Employment or Leadership Position - Novartis
Stock Ownership - Novartis; Novartis (I)
C. Fernandez-Ibarra
No relevant relationships to disclose
A. Dzik-Jurasz
Stock Ownership - Novartis
E. De Vries
No relevant relationships to disclose
S. B. Gaykema
No relevant relationships to disclose
U. Banerji
Employment or Leadership Position - Institute of Cancer Research
Honoraria - Novartis
Research Funding - Novartis